ギラン・バレー症候群患者を対象としたNPB-01の第III相臨床試験

基本情報

NCT ID

NCT02221271

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

22

治験依頼者名

Nihon Pharmaceutical Co., Ltd

概要

Patients diagnosed with Guillain-Barré syndrome were confirmed based on the diagnostic criteria for Guillain-Barré syndrome. Patients who meet all inclusion criteria and do not conflict with the exclusion criteria will receive NPB-01 (intravenous immunoglobulin) 400mg/kg/day for five consecutive days. Patients evaluate the Functional Grade（FG） and Arm Grade（AG） et al. As a safety endpoint, the safety of NPB-01 will be investigated the occurrence of adverse events by the start of the study treatment.

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)